Cabaletta Bio Inc (CABA) concluded trading on Wednesday at a closing price of $1.75, with 13.49 million shares of worth about $23.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.89% during that period and on June 11, 2025 the price saw a loss of about -25.53%. Currently the company’s common shares owned by public are about 50.74M shares, out of which, 46.16M shares are available for trading.
Stock saw a price change of -20.81% in past 5 days and over the past one month there was a price change of 35.66%. Year-to-date (YTD), CABA shares are showing a performance of -22.91% which decreased to -83.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.99 but also hit the highest price of $13.50 during that period. The average intraday trading volume for Cabaletta Bio Inc shares is 1.42 million. The stock is currently trading -10.79% below its 20-day simple moving average (SMA20), while that difference is up 15.93% for SMA50 and it goes to -36.41% lower than SMA200.
Cabaletta Bio Inc (NASDAQ: CABA) currently have 50.74M outstanding shares and institutions hold larger chunk of about 67.14% of that.
The stock has a current market capitalization of $88.80M and its 3Y-monthly beta is at 2.81. It has posted earnings per share of -$2.54 in the same period. It has Quick Ratio of 3.96 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CABA, volatility over the week remained 17.66% while standing at 11.46% over the month.
Stock’s fiscal year EPS is expected to drop by -5.46% while it is estimated to increase by 8.47% in next year. EPS is likely to grow at an annualized rate of 3.54% for next 5-years, compared to annual growth of -20.35% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on December 20, 2024 offering an In-line rating for the stock and assigned a target price range of between $15 and $6 to it. Coverage by Wells Fargo stated Cabaletta Bio Inc (CABA) stock as an Equal weight in their note to investors on December 19, 2024, suggesting a price target of $6 for the stock. On October 10, 2024, UBS Initiated their recommendations, while on February 05, 2024, Jefferies Initiated their ratings for the stock with a price target of $36. Stock get an Outperform rating from William Blair on November 29, 2023.
